Bausch Health (LTS:0QYW) Notes Receivable: CHF0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0QYW Bausch Health Companies Inc LTS:0QYW
65 GF Score
Price CHF122.94
GF Value CHF157.98
! 3 Warning Signs
View Full Analysis

What is Bausch Health Notes Receivable?

Bausch Health LTS:0QYW 65 Notes Receivable is CHF0 Mil as of Jun. 2026. GuruFocus rates LTS:0QYW with a GF Score™ of 65/100 and a GF Value™ of CHF157.98. The stock has 3 warning signs investors should review.

Bausch Health's Notes Receivable for the quarter that ended in Jun. 2026 was CHF0 Mil.

Bausch Health Notes Receivable Historical Data

* Premium members only.

The historical data trend for Bausch Health's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bausch Health Notes Receivable Chart

Bausch Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bausch Health Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0QYW
65GF Score
Bausch Health Companies Inc LTS:0QYW
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bausch Health Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of CHF0 Mil mean?
Bausch Health (LTS:0QYW) has a Notes Receivable of CHF0 Mil as of Jun. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Bausch Health and its competitors.
Is Bausch Health's Notes Receivable too high?
Bausch Health's current Notes Receivable is CHF0 Mil. Overall, Bausch Health has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Bausch Health's Notes Receivable compare to ZTS?
Bausch Health's Notes Receivable of CHF0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Bausch Health and its competitors. Bausch Health's current Notes Receivable is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch Health stock overvalued right now?
Bausch Health (LTS:0QYW) has a current Notes Receivable of CHF0 Mil. The stock's GF Value™ is CHF157.98, compared to a current price of CHF122.94 — trading 22.2% below its estimated fair value. The current Notes Receivable is CHF0 Mil. Bausch Health's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Bausch Health (LTS:0QYW), the current Notes Receivable is CHF0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bausch Health (LTS:0QYW) Overvalued in 2026?

Based on GuruFocus' analysis, Bausch Health stock appears to be undervalued. The current stock price of CHF122.94 is trading 22.2% below its estimated GF Value™ of CHF157.98.

Key valuation signals for LTS:0QYW:

  • Notes Receivable: CHF0 Mil
  • GF Value™: CHF157.98 vs. price of CHF122.94 (22.2% below fair value)
  • GF Score™: 65/100 with 3 warning signs

No single metric tells the full story. See the LTS:0QYW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bausch Health Business Description

Address 2150 St Elzear Boulvard West, Laval, QC, CAN, H7L 4A8
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
65GF Score

Get the complete analysis for LTS:0QYW

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF122.94
Price
CHF157.98
GF Value